Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics of Adalimumab With Methotrexate for Treatment of Patients With Ulcerative Colitis (UC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or non-pregnant, non-lactating females. Females of child bearing potential must have a negative serum pregnancy test prior to randomization, and must use a hormonal (oral, implantable or injectable) or barrier method of birth control throughout the study. Females unable to bear children must have documentation of such in the source records (i.e., tubal ligation, hysterectomy, or post-menopausal \[defined as a minimum of one year since the last menstrual period\]).~* Diagnosis of UC confirmed by established criteria, regardless of disease duration.~* Moderate to severely active UC, defined by a modified Mayo Score ≥6, with confirmed endoscopic activity by central reader (Mayo endoscopic subscore ≥2).~* Require initiation with adalimumab for induction of remission.~* Ability of subject to swallow study drug capsules.~* Ability of subject to participate fully in all aspects of this clinical trial.~* Written informed consent must be obtained and documented.~Exclusion Criteria:~* Prior treatment with a TNF antagonist or biological therapy.~* Prior treatment with MTX.~* Disease limited to the rectum (proctitis).~* Documented presence of antibodies against adalimumab.~* Contraindication for anti-TNF or MTX therapy.~* Contraindication for endoscopy.~* Ostomy.~* Planned surgery.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- MTX 12.5 (Type: ACTIVE_COMPARATOR): Receive once weekly oral dosing with MTX 12.5 mg (n=40) two weeks prior to the initiation of adalimumab 18 weekly doses of MTX and/or placebo in addition to doses of adalimumab
- MTX 25 mg (Type: ACTIVE_COMPARATOR): Once weekly oral dosing with MTX 25 mg (n=40) two weeks prior to the initiation of adalimumab 18 weekly doses of MTX in addition to doses of adalimumab
- Placebo (Type: PLACEBO_COMPARATOR): Once weekly oral dosing with placebo (n=20) two weeks prior to the initiation of adalimumab. Subjects will receive 18 weekly doses of placebo in addition to doses of adalimumab

Based on this trial design, predict the completion outcome and termination type (if applicable).